Adverse Drug Reactions in Anti-Tuberculosis Therapy with Special Emphasis on Rifampicin: A Review
International Journal of Pharmaceutical Sciences Review and Research · 2026-06 · 86 (6)
DOI: 10.47583/ijpsrr.2026.v86i6.033 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Pharmaceutical Sciences Review and Research, 2026-06. Verfasst von Vaishnavi V Bhosale und 6 weiteren Autor:innen.
Abstract (Originalsprache)
Tuberculosis (TB) remains a significant global health burden, necessitating prolonged combination therapy with first-line antituberculosis drugs (ATDs).Despite their efficacy, these drugs are frequently associated with adverse drug reactions (ADRs), which can negatively impact patient adherence and treatment outcomes.Among these, hepatotoxicity is one of the most serious and commonly reported complications, particularly associated with isoniazid and rifampicin.Isoniazid undergoes hepatic metabolism to form toxic intermediates that may induce liver injury.Rifampicin, a cornerstone of anti-TB therapy due to its potent bactericidal activity, is also associated with a wide spectrum of ADRs, including hepatotoxicity, hypersensitivity reactions, gastrointestinal disturbances, and significant drug-drug interactions due to enzyme induction.The occurrence and severity of ADRs are influenced by multiple factors such as age, comorbidities, nutritional status, alcohol consumption, and genetic variability.Pharmacogenomic insights have increasingly highlighted the role of genetic profiling in predicting susceptibility to ADRs and guiding individualized therapy.This review provides a comprehensive overview of ADRs associated with anti-tuberculosis therapy, with special emphasis on rifampicin.It discusses the underlying mechanisms, risk factors, and the role of genetic determinants in modulating drug response.Additionally, strategies for monitoring, early detection, prevention, and management of ADRs are emphasized.Early recognition and appropriate intervention are crucial for improving treatment adherence and achieving favourable clinical outcomes.Overall, integrating pharmacogenomic approaches with clinical monitoring may significantly enhance the safety and efficacy of TB treatment.
Zitieren
APA
Bhosale, V. V., Mohite, N. C., Devade, O. A., Jadhav, P. D., Kolekar, S. T., Dalavi, C. S., & Shaikh, R. M. (2026). Adverse Drug Reactions in Anti-Tuberculosis Therapy with Special Emphasis on Rifampicin: A Review. International Journal of Pharmaceutical Sciences Review and Research, 86(6). https://doi.org/10.47583/ijpsrr.2026.v86i6.033
Vancouver
Bhosale VV, Mohite NC, Devade OA, Jadhav PD, Kolekar ST, Dalavi CS, et al. Adverse Drug Reactions in Anti-Tuberculosis Therapy with Special Emphasis on Rifampicin: A Review. International Journal of Pharmaceutical Sciences Review and Research. 2026;86(6). doi:10.47583/ijpsrr.2026.v86i6.033
BibTeX
@article{Bhosale2026,
author = {Bhosale, Vaishnavi V and Mohite, Nikita C and Devade, Omkar A and Jadhav, Prakash D and Kolekar, Sonali T and Dalavi, Chaitali S and Shaikh, Rahim M},
title = {Adverse Drug Reactions in Anti-Tuberculosis Therapy with Special Emphasis on Rifampicin: A Review},
journal = {International Journal of Pharmaceutical Sciences Review and Research},
year = {2026},
volume = {86},
number = {6},
doi = {10.47583/ijpsrr.2026.v86i6.033}
}
EUVIMED